Hexarelin: Uses, Benefits & Research

What is Hexarelin?

Hexarelin (examorelin, His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, MW 933.1 Da) is a second-generation synthetic hexapeptide and the most potent growth hormone-releasing peptide in the GHRP family. The D-2-Methyl-Trp substitution provides enhanced metabolic stability compared to first-generation compounds like GHRP-6.

What makes Hexarelin unique among all GHRPs is its dual-receptor profile: it activates both the GHSR-1a receptor for GH release (shared with all GHRPs) and the CD36 scavenger receptor in cardiac tissue (unique to Hexarelin). This cardiac binding produces potential cardioprotective effects not available from any other GHRP. Additionally, Hexarelin produces the least appetite stimulation of any GHRP, making it preferred when orexigenic effects are undesirable. It has an estimated half-life of 1.5-2 hours and subcutaneous bioavailability of 75-85%. Hexarelin has never received FDA approval and is WADA-prohibited since 2008.

Mechanism of Action

Hexarelin’s primary mechanism involves potent GHSR-1a agonism in pituitary somatotrophs, producing the highest peak GH levels of any GHRP — approximately 2x GHRP-2 at equimolar doses. This leads to consistent downstream IGF-1 elevation.

The distinguishing secondary mechanism is CD36 receptor binding in cardiac tissue. CD36 is a scavenger receptor involved in fatty acid metabolism, and Hexarelin’s activation of this pathway produces coronary vasodilation and cardioprotective effects demonstrated in animal models. Human data has shown improved left ventricular ejection fraction in both normal and GH-deficient subjects, though not in severe dilated cardiomyopathy.

Hexarelin’s minimal activation of hypothalamic appetite pathways results in the lowest orexigenic effect of any GHRP, making it more selective for GH release without the hunger-driven side effects.

Clinical Evidence

Human Studies

Hexarelin has 3-5 RCTs and 8-12 total human studies, with unique cardiac data not seen with other GHRPs.

GH Potency Comparison Trial (2004): RCT (N=30 healthy adults) comparing GHRP-2, GHRP-6, and Hexarelin confirmed Hexarelin produced the highest peak GH level at equimolar doses.

Cardiac Function Study (2002): Clinical trial (N=24) by Bodart et al. demonstrated increased left ventricular ejection fraction in normal and GH-deficient subjects following 100 mcg IV Hexarelin. No effect was seen in severe dilated cardiomyopathy (PMID: 11988484).

GH/IGF-1 in GH-Deficient Adults: Phase II RCT (N=40) using 100 mcg subcutaneous daily for 30 days showed significant IGF-1 elevation and improved GH secretory pattern.

Coronary Artery Bypass Surgery Trial: Clinical trial (N=20 CABG patients) showed acute Hexarelin administration improved cardiac output post-surgery.

No active clinical trials exist as of 2026.

Preclinical Evidence

Animal studies have demonstrated CD36-mediated cardioprotection including coronary vasodilation and improved cardiac function in ischemia models. The CD36 pathway also shows potential for atheroprotection and fatty acid metabolism modulation.

Drug Interactions & Contraindications

Glucocorticoids are documented to attenuate Hexarelin’s GH-releasing effects. Theoretical interactions include GHRH analogs (synergistic — combined use produces superphysiological GH levels), somatostatin analogs (may attenuate effect), beta-blockers and cardiac medications (CD36-mediated cardiac effects may interact), and CD36 ligands involved in fatty acid metabolism.

Hexarelin is contraindicated in active malignancy, cardiovascular disease (due to CD36 cardiac receptor activity), and pregnancy/breastfeeding. The dual-receptor mechanism adds regulatory complexity compared to other GHRPs.

Safety & Side Effects

From human trials, commonly reported effects include headache, transient cortisol and prolactin elevation, and injection site reactions (less frequent than GHRP-6). Notably absent are significant appetite increase and water retention — distinguishing Hexarelin from other GHRPs.

The primary unresolved safety question concerns the long-term effects of chronic CD36 receptor activation. Acute cardioprotection has been demonstrated, but whether chronic stimulation (months to years) is beneficial or harmful remains completely unknown. Theoretical concerns also include cancer risk from GH/IGF-1 elevation, glucose metabolism effects, and potential cardiac remodeling from sustained CD36 activation.

Honest Bottom Line

Hexarelin is the most potent GH-releasing peptide in the GHRP family, with 3-5 RCTs and the unique distinction of CD36 cardiac receptor binding for potential cardioprotective effects. It produces the least appetite stimulation of any GHRP, making it suitable when orexigenic effects are undesirable. However, it has never received FDA approval, no active clinical trials exist as of 2026, and its long-term cardiac safety from CD36 pathway activation remains uncharacterized. Hexarelin represents a Tier 3 compound with moderate human evidence and unique therapeutic potential, but patients should understand the evidence gap around chronic cardiac effects.